Supha Pharmachem Q4 Results FY26

Supha Pharmachem Ltd has announced its Q4 FY26 financial results, revealing significant insights into the company’s performance during the quarter. With a revenue of Rs. 111.06 crore, a net profit of Rs. 8.62 crore, and an earnings per share (EPS) of Rs. 0.10, the results underline the company’s financial trajectory. Investors and stakeholders are keen to understand the implications of these numbers, as well as the overall performance of the company in comparison to previous quarters.

In this article, we take a closer look at the key highlights of Supha Pharmachem’s Q4 FY26 results, including revenue performance, net profit, EPS, and other financial metrics.

The latest quarterly results of Supha Pharmachem Ltd for Q4 FY26 provide a comprehensive view of the company’s financial health and operational performance. With a reported revenue of Rs. 111.06 crore and a net profit of Rs. 8.62 crore, the company has showcased steady growth. These results are critical for investors seeking to understand the company’s financial stability and the potential for future returns.

Supha Pharmachem Ltd, a key player in the pharmaceutical and chemical industry, has released its financial results for the fourth quarter of FY26. The company reported a revenue of Rs. 111.06 crore, reflecting its ability to maintain a strong market presence. Additionally, the net profit stood at Rs. 8.62 crore, while the EPS was reported at Rs. 0.10.

These figures highlight the company’s steady financial performance, making it a point of interest for investors and stakeholders. With a focus on innovation and operational efficiency, Supha Pharmachem continues to strengthen its position in the competitive pharmaceutical market.

The revenue performance of Supha Pharmachem in Q4 FY26 underscores its solid market presence and operational efficiency. The company reported a total revenue of Rs. 111.06 crore during the quarter, showcasing its ability to generate consistent income despite market fluctuations.

Revenue Breakdown for Q4 FY26

This performance demonstrates the company’s resilience and its ability to maintain steady operations in a competitive industry.

Supha Pharmachem’s net profit for Q4 FY26 stood at Rs. 8.62 crore, reflecting its efficient cost management and strong revenue generation. The company’s profitability metrics indicate a stable financial standing, which is a positive sign for its investors.

The net profit figure represents the company’s ability to convert revenue into profit, showcasing its operational efficiency and market competitiveness. This performance is likely to bolster investor confidence and pave the way for future growth.

Earnings per share (EPS) is a critical metric for evaluating a company’s profitability and its ability to generate returns for shareholders. In Q4 FY26, Supha Pharmachem reported an EPS of Rs. 0.10.

Key Financial Metrics

These financial metrics provide valuable insights into the company’s profitability and efficiency, making it an attractive option for potential investors.

A quarter-on-quarter comparison of Supha Pharmachem’s financial performance reveals the company’s ability to maintain stability and growth. Below is a comparison of key metrics from Q4 FY26 and Q3 FY26:

The quarter-on-quarter growth in revenue and net profit highlights the company’s consistent performance and its ability to adapt to market dynamics.

Supha Pharmachem Ltd is a prominent player in the pharmaceutical and chemical industry, specialising in the production and distribution of high-quality chemical products. The company is known for its innovative solutions and commitment to quality, which have helped it establish a strong foothold in the market.

With a diverse product portfolio catering to various industries, Supha Pharmachem continues to drive growth and innovation, ensuring its relevance in an ever-evolving market landscape.

For investors, Supha Pharmachem’s Q4 FY26 results provide several key takeaways:

• Stable Revenue Growth: The company reported a revenue of Rs. 111.06 crore, reflecting consistent growth.
• Profitability Metrics: With a net profit of Rs. 8.62 crore and an EPS of Rs. 0.10, the company has demonstrated strong profitability.
• Quarter-on-Quarter Improvement: The company achieved a 2.36% increase in revenue and a 5.12% rise in net profit compared to Q3 FY26.
• Market Resilience: Supha Pharmachem’s ability to maintain steady performance highlights its resilience in a competitive market.
• Potential for Growth: The company’s focus on innovation and operational efficiency positions it well for future growth.

If you are considering investing in Supha Pharmachem, here are the steps to follow using your demat account:

1. Open a demat account: If you do not already have one, choose a reliable broker and open a demat account.
2. Complete KYC process: Provide the required documents for identity and address verification.
3. Link your bank account: Ensure your bank account is linked to your demat account for seamless transactions.
4. Search for Supha Pharmachem shares: Use your broker’s platform to locate Supha Pharmachem Ltd shares.
5. Place your order: Decide the number of shares you wish to purchase and place your buy order.
6. Monitor your investment: Regularly review your investment to track performance and make informed decisions.

Investments in securities markets are subject to market risks. Please read all scheme-related documents carefully before investing.

Supha Pharmachem’s Q4 FY26 results highlight the company’s strong financial standing and consistent performance. With a revenue of Rs. 111.06 crore, a net profit of Rs. 8.62 crore, and an EPS of Rs. 0.10, the company has demonstrated its resilience and potential for future growth. For investors, these results provide a positive outlook, showcasing the company’s ability to maintain profitability and adapt to market dynamics.

As always, investors should conduct thorough research and consider consulting a financial advisor before making any investment decisions. Past performance is not indicative of future returns.